Epidemiological evidence suggests that plasma high-density lipoprotein (HDL) is protective against coronary artery disease, whereas oxidatively modified low density lipoprotein is atherogenic. Human apolipoprotein A-I transgenic mice with overexpression of the human apolipoprotein A-I gene have increased plasma levels of apolipoprotein A-I and HDL-cholesterol. We analyzed LDL oxidation by determination of LDL associated malondialdehyde, peroxides and conjugated dienes. The present study demonstrates that HDL from both normal and human apolipoprotein A-I transgenic mice at similar concentrations inhibits LDL (protein concentration 500 mg/1) lipid peroxidation, but the effect of the human apolipoprotein A-I transgenic mice HDL was two-fold greater than that of HDL derived from normal mice. In addition, the electrophoretic mobility of oxidatively modified LDL was reduced about two-fold in the presence of human apolipoprotein A-I transgenic mice HDL than that obtained in the presence of normal mice HDL. We thus suggest that human apolipoprotein A-I possesses antioxidant properties which might neutralize LDL lipid peroxidation. This may underline the mechanism responsible for the lower prevalence of atherosclerosis in subjects with high plasma levels of HDL and apolipoprotein A-I.
Introduction
which HDL might protect against the atherosclerotic " . , . , . , ,. , , . t . process in addition to its role in reverse cholesterol Epidemiological studies have shown an inverse relation ^_ __ transport. between plasma HDL cholesterol levels and coronary artery disease (1) (2) (3) (4) . However, the underlying mecha-Recently, the transgenic mouse model with overexpresnisms responsible for this protective action of HDL are sion of the human apolipoprotein A-I gene has been denot yet well established. The most widely accepted hy-scribed (14, 15) . These animals have increased levels of pothesis is that HDL facilitates reverse cholesterol trans-apolipoprotein A-I and HDL-cholesterol, which, in turn, port (5) (6) (7) (8) , but other mechanisms, such as the protective may be responsible for their resistance to atheroscleroeffect of HDL on vessel wall and the possible effect sis. Rubin et al. (16) have recently demonstrated that the of HDL on the atherogenic apolipoprotein B containing atherosclerotic lesion is significantly reduced in human lipoproteins, may also be important (9) . apolipoprotein A-I transgenic mice compared to control littermates after 4 months on a high cholesterol diet. Several lines of evidence suggest that LDL oxidation contributes to atherosclerosis (8, 10, 11 (20) . lesions (12, 13) . Possible HDL-mediated inhibition of The present study was undertaken in order to explore LDL oxidation may be an additional mechanism by the potential protective effect of human apolipoprotein Eur J Clin Chem Clin Biochem 1995; 33 (No 10) A-I against HDL lipid pcroxidation by using mice HDL derived from human apolipoprotein A-I transgenic (HuAITg) mice.
Methods
Human apolipoprotein A-l transgenic mice were kindly provided to us by Dr. Jan Breslow, The Rockefeller University, New York, U. S. A. Transgenic mice expressing the human apolipoprotein Α-Ι gene have increased plasma levels of human apolipoprotein A-I and HDL cholesterol (14, 15) . Blood was collected from the retroorbital plexus under anesthesia with ether (14, 21) into Eppendorf tubes with 1 mmol/1 Na?EDTA. Lipoproteins (VLDL, d < 1.006 kg/1; LDL, d = 1.006-1.063 kg/1; HDL, d = 1.063-1.210 kg/1) were isolated from 3 ml of pooled plasma from human apolipoprotein A-l transgenic mice or from control littermates by sequential ultracentrifugation as previously described (14, 21) . Human LDL was isolated from healthy volunteers' plasma by the same method. The isolated lipoproteins were dialyzed against 150 mmol/1 NaCl, l mmol/1 EDTA, pH 7.4. Plasma cholesterol in lipoproteins was determined by enzymatic methods (14) . Human apolipoprotein Α-Ι levels were measured by a turbidimetric immunoassay applied for semiautomatic analyzer (22) and protein was measured by the method of Lowry et al. (23) .
Plasma concentration of human apolipoprotein A-I in a representative group of human apolipoprotein A-I transgenic mice was 2800 ± 300 mg/1 compared to mouse apolipoprotein A-I levels of 1500 ±200 mg/1 in normal littermates, and plasma HDL cholesterol concentration was 880 ± 30 mg/1, compared to HDLcholesterol of 490 ± 30 mg/1 (n = 8) in controls. It was previously shown (24, 25) that, in human apolipoprotein A-I transgenic mice, the major plasma apolipoprotein is human apolipoprotein A-l and their HDL pattern is human-like with both HDL 2 and HDL 3 subtractions (in normal mice only o.ne HDL fraction, which is HDL 2 , exists).
LDL oxidation was induced after an overnight dialysis of the lipoprotein against EDTA-free phosphate buffered saline. The lipoproteins were then diluted with phosphate buffered saline to a final protein concentration of 0.5 gA. In order to compare the effect of HDL derived from human apolipoprotein A-I transgenic mice to that of control HDL derived from normal mice on LDL oxidation, human LDL (protein concentration 1500 mg/l) was incubated with control HDL or with human apolipoprotein A-I transgenic mice HDL (protein concentration 0.5 g/1) in the presence of 10 μιηοΐ/ΐ CuSO 4 for 3 h at 37 °C. Lipoprotein oxidation was terminated by refrigeration and the addition of 1 mmol/1 Na 2 EDTA. The oxidative state of the lipoproteins was assayed by determination of the thiobarbituric acid reactive substance assay (26) , the content of conjugated dienes at 234 nm (27) and lipid peroxide formation using a commercially available kit (CHOD iodide method, Diagnostic® Merck, Darmstadt, Germany) based on the ability of lipid peroxides to convent iodide to iodine (28) . Similar analyses were performed on lipoproteins that were incubated under non-oxidative stress (in the absence of CuSO 4 ). In addition, the lag time and the kinetics of LDL and HDL oxidation was determined by monitoring the changes measured at 234 nm in absorbance, observed at room temperature (23 °C) of freshly isolated human LDL (protein concentration 200 mg/1 of phosphate buffered saline), control mouse HDL (protein concentration 200 mg/1), human apolipoprotein A-I transgenic mice HDL (protein concentration 200 mg/1), mixtures of human LDL and control mouse HDL or human LDL and human apolipoprotein A-I transgenic mouse HDL in the concentrations indicated above, following incubation with CuSO 4 (10 μηιοΐ/ΐ). Absorbance was recorded every 10 minutes for a period of 3 hours. The effect of HDL from human apolipoprotein A-I transgenic mice or from control littermates on human LDL oxidation was also assessed by agarose gel electrophoresis. This was carried out on 0.7% agarose gels at pH 8.6 in 0.05 mol/1 barbital buffer (29) , and the electrophoretic mobility of oxidized LDL under the various experimental conditions was measured.
Results
The susceptibility of human LDL (p f rotein concentration 500 mg/1) to undergo lipid peroxidation under oxidative stress (10 μιηοΐ/ΐ CuSO 4 ) was analyzed in the presence of HDL (protein concentration 500 mg/1) derived from normal or from human apolipoprotein A-I transgenic mice.
Both human LDL and HDL from normal mice were oxidized when incubated with 10 μιηοΐ/ΐ CuSO 4 for 3 h at 37 °C ( fig. 1 ). The susceptibility of human LDL to lipid peroxidation was considerably higher than that of the HDL from the normal mice with 2-fold increase in malondialdehyde levels, 11-fold increase in the peroxide content and 4-fold increase in LDL conjugated dienes content ( fig. la-c) . We then tested the effect of HDL from the control mice on the oxidizability of human LDL. The measured lipid peroxidation rate of human LDL that was incubated together with HDL from the normal mice was 25%, 22% and 28% lower for malondialdehyde, peroxide and conjugated dienes, respectively, than the expected oxidation, calculated by adding LDL and HDL lipid peroxidation rates ( fig. la-c) .
We next studied the effect of HDL from human apolipoprotein A-I transgenic mice on human LDL susceptibility to lipid peroxidation. The lipid peroxidation rate . of HDL from human apolipoprotein A-I transgenic mice was significantly higher (p < 0.01) than that of normal mice HDL (see fig. 2, HDL vs fig. 1, HDL) . The effect of HDL from human apolipoprotein A-I transgenic mice on human LDL susceptibility to lipid peroxidation was then analyzed. The measured lipid peroxidation of human LDL when incubated together with HDL from human apolipoprotein A-I transgenic mice was 51%, 34% and 54% lower than the expected lipid peroxidation as calculated by adding the lipoprotein lipid peroxidation rates for malondialdehyde, peroxide and conjugated dienes, respectively ( fig. 2a-c) . These results demonstrate that HDL from human apolipoprotein A-I transgenic mice inhibits human LDL lipid peroxidation by about 50%, a 2-fold higher inhibitory effect on human LDL oxidation in comparison to the effect of HDL from normal mice. Kinetic analysis of Cu 24 " induced LDL oxidation revealed similar results, suggesting that both human apolipoprotein A-I transgenic and control mouse HDL not only attenuate the maximal final level of LDL oxidation but also delay the oxidative process of LDL.
The lag time for human LDL oxidation was 48 minutes, whereas, upon incubation of the human LDL with con-trol HDL as well as with human apolipoprotein A-I transgenic mice HDL, the lag time was significantly decreased to 35 and 34 minutes, respectively, again indicating the inhibitory effect of both HDL preparations on LDL oxidation. Of special interest was the finding that, whereas the lag time of the oxidation of control HDL was 46 minutes, on using human apolipoprotein A-I transgenic mice HDL, the lag time was as short as 25 minutes. This latter result suggests that human apolipoprotein A-I transgenic mouse HDL is a more potent antioxidant than control mouse HDL which can be attributed to its higher capacity to undergo lipid peroxidation. A similar pattern was found on calculating the slope of the propagation phase of LDL oxidation (data not shown).
LDL lipid peroxidation is associated with increased electrophoretic mobility. The electrophoretic mobility of human LDL (protein concentration 500 mg/1) was measured following its incubation with HDL (protein concentration 500 mg/1) derived from normal mice or from human apolipoprotein A-I transgenic mice in the absence or presence of 10 μπιοΐ/ΐ CuSO 4 for 3 h at 37 °C (tab. 1). LDL lipid peroxidation in the presence of copper ions increased the electrophoretic mobility of native LDL by 30% (tab. la,b). In the presence of HDL from normal mice, the electrophoretic migration of the oxidized LDL was reduced by only 11% in comparison to oxidized LDL alone (tab. lb,d). The addition of HDL from human apolipoprotein A-I transgenic mice (tab. If) further inhibited the migration of human LDL up to 19% in comparison to oxidized LDL (tabl. Ib). In the absence of copper ions, no effect of either HDL preparation could be found.
Discussion
Several lines of evidence suggest that plasma HDL levels inversely correlate with coronary artery disease (1-4). The exact mechanism by which HDL protects against atherosclerosis, however, is not known. The inhibitory effect of human apolipoprotein A-I on LDL oxidation may suggest an additional mechanism whereby HDL might attenuate the atherosclerotic process in addition to its well accepted role in reverse cholesterol transport (5-8).
Our study demonstrates that HDL from either normal or human apolipoprotein A-I transgenic mice inhibits LDL lipid peroxidation, but the effect of human apolipoprotein A-I transgenic mice HDL was substantially greater than that of HDL derived from normal mice, suggesting that human apolipoprotein A-I possesses additional antioxidative characteristics. (28, 31) . In our study we used human apolipoprotein A-I transgenic mice HDL in which the HDL pattern is human-like with HDL 2 and HDL 3 subtractions, compared to HDL from normal mice in which the HDL comprises just one component which approximates HDL 2 in size. This may explain the higher capacity of human apolipoprotein A-I transgenic HDL (which contains both HPL 2 and HDL 3 ) to inhibit LDL oxidation than HDL from the normal mice.
Breslow et al. recently demonstrated (9) that by cross breeding human apolipoprotein A-I transgenic mice with apolipoprotein Ε-deficient mice, the plasma HDL cholesterol levels were elevated by 2-fold in comparison to apolipoprotein Ε-deficient mice HDL-cholesterol and atherosclerotic lesions were significantly less pronounced (9). Rubin et al. (32) also demonstrated that the apolipoprotein A-I transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. This latter effect may involve HDL-mediating prostaglandin transport (33) , as well as the inhibitory effect of apolipoprotein A-I on LDL lipid peroxidation in the arterial wall.
Interestingly, our study demonstrates that the lipid peroxidation of human apolipoprotein A-I transgenic mice HDL is considerably greater than that of normal mice HDL. This higher propensity of human apolipoprotein A-I transgenic mice HDL for oxidation may be related to the mechanism by which human apolipoprotein Α-Ι in human apolipoprotein A-I transgenic mice HDL protects against lipid peroxidation of human LDL.
Parthasarathy et al. also suggested that HDL may play a protective role in atherogenesis by preventing the generation of oxidatively modified LDL (34) by a mechanism which involves the exchange of lipid peroxidation products between the LDL and HDL. This mechanism may also operate with apolipoprotein A-I in HDL from human apolipoprotein A-I transgenic mice as demonstrated by its higher oxidizability ίη comparison to that of normal mice.
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In conclusion, the present study demonstrated that human apolipoprotein A-I possesses significant antioxidative properties against LDL lipid peroxidation, and this may underline the mechanism responsible for the protective effect observed in subjects with increased plasma concentrations of apolipoprotein A-I (4).
